Skip to main content
Sailong Pharmaceutical Group Co., Ltd. logo

Sailong Pharmaceutical Group Co., Ltd. — Investor Relations & Filings

Ticker · 002898 ISIN · CNE1000032S5 LEI · 8368004F5Y6BSB6US681 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,117 across all filing types
Latest filing 2020-08-10 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 002898

About Sailong Pharmaceutical Group Co., Ltd.

https://www.sailong.cn

Sailong Pharmaceutical Group Co., Ltd. is a pharmaceutical enterprise focused on the research, development, production, and marketing of high-end generic drugs and innovative formulations. The company maintains an integrated industrial chain encompassing active pharmaceutical ingredients (APIs) and finished dosage forms. Its product portfolio primarily targets therapeutic areas such as cardiovascular and cerebrovascular diseases, the digestive system, and anti-infective treatments. Key products include Monosialotetrahexosylganglioside Sodium Injection and Pantoprazole Sodium for Injection. The group emphasizes technological innovation and quality control to provide clinical solutions for complex medical conditions.

Recent filings

Filing Released Lang Actions
第二届董事会第二十六次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 26th meeting of the second board of directors of Zhuhai Sailong Pharmaceutical Co., Ltd. It includes details about the meeting's convening, attendance, and voting results on several agenda items such as approval of the 2020 semi-annual report, a special report on the use of raised funds, and changes in accounting policies. The document does not contain the full semi-annual report or detailed financial statements but refers to these reports being published separately on a public information website. The document is primarily a board meeting resolution announcement, which fits the category of Board/Management Information (MANG). The document length is short (1449 characters), and it serves as an announcement of board decisions rather than the report itself, so it is not an Interim/Quarterly Report (IR) or Annual Report (10-K). Therefore, the correct classification is MANG with high confidence.
2020-08-10 Chinese
2020年半年度财务报告
Interim / Quarterly Report Classification · 100% confidence The document is titled as a "2020 年半年度财务报告" which translates to "2020 Half-Year Financial Report". It contains detailed financial statements including consolidated and parent company balance sheets, income statements, cash flow statements, and notes to the financial statements. The data covers the half-year period ending June 30, 2020. The length of the document is substantial (15,000 characters), and it includes actual financial data and analysis rather than just an announcement or certification. This matches the definition of an Interim / Quarterly Report (IR), which is a comprehensive financial report for a period shorter than a full fiscal year containing substantive financial data and analysis. Therefore, the document should be classified as an Interim / Quarterly Report (IR). H1 2020
2020-08-10 Chinese
2020年半年度报告摘要
Interim / Quarterly Report Classification · 100% confidence The document is titled as a "2020 年半年度报告摘要" which translates to "2020 Semi-Annual Report Summary." It contains detailed financial data such as revenue, net profit, assets, liabilities, and equity for the half-year period ending June 30, 2020. It also includes management discussion and analysis of business operations, accounting policy changes, and other financial metrics. The length of the document is over 10,000 characters, indicating it is a substantive report rather than a brief announcement. The content matches the characteristics of an Interim / Quarterly Report, which is a comprehensive financial report for a period shorter than a full fiscal year and includes actual financial statements and analysis. Therefore, the appropriate classification is Interim / Quarterly Report (IR). H1 2020
2020-08-10 Chinese
关于公司2019年年报问询函的回复
Audit Report / Information Classification · 95% confidence The document is a detailed response letter from an accounting firm (致同会计师事务所) to the Shenzhen Stock Exchange regarding inquiries about the 2019 annual report of 珠海赛隆药业股份有限公司. It discusses the audit of the 2019 financial statements, including balance sheets, profit and loss statements, cash flow statements, and notes. The document includes detailed explanations about the capitalization of R&D expenditures, compliance with accounting standards, and comparisons with industry peers. It also references the audit report issued on April 28, 2020, and the inquiry letter from the stock exchange dated July 17, 2020. The content is focused on audit findings and responses to regulatory inquiries about the annual report, rather than the annual report itself or a simple announcement. The document contains substantive financial and audit information related to the annual report but is not the annual report itself. It is a standalone audit-related response document, fitting the category of Audit Report / Information (AR). The document length (6535 characters) and detailed content support this classification rather than a brief announcement or certification. FY 2019
2020-07-29 Chinese
关于深圳证券交易所2019年年报问询函的回复公告
Annual Report Classification · 95% confidence The document is a detailed response from Zhuhai Sailong Pharmaceutical Co., Ltd. to an inquiry letter from the Shenzhen Stock Exchange regarding the company's 2019 annual report. It contains extensive financial data, explanations of cash flow, government subsidies, R&D capitalization, fixed assets, sales expenses, and auditor's opinions. The content is focused on clarifying and supplementing information related to the 2019 annual report, including financial figures and accounting treatments. The document length is over 11,000 characters and includes substantive financial data and analysis. This is not a mere announcement or certification but a comprehensive report addressing regulatory inquiries about the annual report. Therefore, it fits best as an Annual Report (10-K) type filing, as it covers the company's full financial performance and related disclosures for the fiscal year 2019. FY 2019
2020-07-29 Chinese
2020年半年度业绩预告
Earnings Release Classification · 95% confidence The document is a performance forecast for the half-year period ending June 30, 2020, issued by the company's board. It includes estimated net profit and earnings per share figures, mentions that the forecast is unaudited, and explains reasons for performance changes. It explicitly states that the final detailed financial data will be in the company's 2020 half-year report. The document is short (957 characters) and serves as a preliminary earnings forecast rather than a full interim or quarterly report containing actual financial statements. Therefore, it fits best as an Earnings Release (ER), which is the initial announcement of periodic financial results with key highlights only. H1 2020
2020-07-14 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.